EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study

Marcin Krawczyk iD, Frank Grünhage iD, Lisa Schubert, Nektarios Dikopoulos, Jeannette Schwenzer, Marion Muche, Johannes Wiegand iD, Gisela Felten, Renate Heyne, Patrick Ingiliz iD, Anna Schmidt, Kerstin Stein und 8 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70298 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Marcin Krawczyk und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: 17-Hydroxysteroid Dehydrogenases, Lipase, Membrane Proteins, Fatty Liver. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Patients We analysed blood samples of 507 patients recruited within the Fatty Liver Assessment in Germany (FLAG) study, of whom 476 (255 males, age 56 years) were genotyped. FLAG is a multicenter real‐world MASLD cohort covering secondary and tertiary healthcare levels. The PNPLA3 p.I148M and the HSD17B13 rs72613567 polymorphisms were genotyped using allelic discrimination assays. The control cohort comprised 174 individuals.

Results

The PNPLA3 p.I148M variant was prevalent among FLAG patients ( p < 0.001 for the departure from Hardy–Weinberg equilibrium) and increased the risk of developing MASLD (common OR = 2.46, p = 6.238e‐09). It was associated with increased ALT and AST, lower serum triglyceride concentrations, and independently with liver stiffness ≥ 9.1 kPa after adjustment for BMI and diabetes (OR = 2.57, p = 0.01). Carriers of the HSD17B13 rs72613567 variant had lower AST. HSD17B13 heterozygotes had lower FIB‐4 ( p = 0.028) and lower liver stiffness ( p = 0.034). Among carriers of the PNPLA3 p.148M allele, the presence of the HSD17B13 variant was associated with lower ALT ( p = 0.023) and AST ( p = 0.041); however, HSD17B13 did not abrogate the association of PNPLA3 with liver fibrosis (adjusted p = 0.013).

Discussion

By analysing a real‐world MASLD cohort in Germany, we further underscore the role of the PNPLA3 variant as the central genetic trigger and modulator of MASLD. The HSD17B13 polymorphism may exert protective effects in MASLD and could attenuate some PNPLA3 ‐associated effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

17-Hydroxysteroid DehydrogenasesLipaseMembrane ProteinsFatty LiverHumansMaleMiddle AgedAcyltransferasesFemaleGermanyPhospholipases A2, Calcium-IndependentGenetic Predisposition to DiseasePolymorphism, Single NucleotideRisk FactorsAgedCohort StudiesGenotypeLiverAdultAlanine TransaminaseAspartate AminotransferasesTriglycerides

Substanzen

AcyltransferasesPhospholipases A2, Calcium-IndependentPNPLA3 protein, human17-Hydroxysteroid DehydrogenasesLipaseMembrane ProteinsHSD17B13 protein, humanAlanine TransaminaseAspartate AminotransferasesTriglycerides

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
  • KRH Klinikum Siloah, Hannover, Germany.
  • Gastroenterologie am Bayerischen Platz, Berlin, Germany.
  • Gastroenterologische Schwerpunktpraxis, Dornstadt, Germany.
  • Bauchzentrum Biesdorf, Berlin, Germany.
  • Charité Campus Benjamin Franklin, Berlin, Germany.

ORCID-Profile: Marcin Krawczyk, Frank Grünhage, Johannes Wiegand, Patrick Ingiliz, Susanne N Weber, Heiner Wedemeyer, Peter Buggisch, Frank Lammert, Jörn M Schattenberg

Zitieren

APA

Krawczyk, M., Grünhage, F., Schubert, L., Dikopoulos, N., Schwenzer, J., Muche, M., Wiegand, J., Felten, G., Heyne, R., Ingiliz, P., Schmidt, A., Stein, K., Weber, S. N., Wedemeyer, H., Zeuzem, S., Buggisch, P., Lammert, F., Geier, A., Hofmann, W. P., & Schattenberg, J. M. (2026). Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70298

Vancouver

Krawczyk M, Grünhage F, Schubert L, Dikopoulos N, Schwenzer J, Muche M, et al. Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70298

BibTeX
@article{Krawczyk2026,
  author = {Krawczyk, Marcin and Grünhage, Frank and Schubert, Lisa and Dikopoulos, Nektarios and Schwenzer, Jeannette and Muche, Marion and Wiegand, Johannes and Felten, Gisela and Heyne, Renate and Ingiliz, Patrick and Schmidt, Anna and Stein, Kerstin and Weber, Susanne N and Wedemeyer, Heiner and Zeuzem, Stefan and Buggisch, Peter and Lammert, Frank and Geier, Andreas and Hofmann, Wolf Peter and Schattenberg, Jörn M},
  title = {Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70298}
}
Kostenlos starten →